GlassScriptPhysician profile
Meera Ranganathan
NPI 1245281948
$2,194.18
in general payments reported to CMS, 2019-2025
26 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.00 · 2022: $48.96 · 2023: $97.08 · 2024: $526 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $403.83 | 2024-2025 | |
| Glaxosmithkline, LLC. | $301.70 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Harmony Biosciences LLC | $197.46 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $164.41 | 2024-2025 | |
| Insmed, INC. | $152.83 | 2022-2025 | Arikayce, Brinsupri |
| Inspire Medical Systems, INC. | $139.07 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $138.27 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Baxter Healthcare | $88.59 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $72.03 | 2024-2025 | Glassia |
| Grifols USA, LLC | $62.86 | 2022-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.34 | 2024 | Ofev |
| Olympus Corporation of The Americas | $54.00 | 2019 | |
| Ani Pharmaceuticals, INC. | $44.75 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $44.40 | 2024-2025 | Tezspire |
| Ethicon INC. | $30.35 | 2025 | Monarch Platform |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $26.81 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $26.12 | 2025 | Dupixent |
| Blueprint Medicines Corporation | $25.28 | 2023 | Ayvakit |
| Philips North America LLC | $24.97 | 2024 | (Ak6) Vest Therapy |
| Pulmonx Corporation | $23.73 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Actelion Pharmaceuticals US, INC. | $22.40 | 2025 | Uptravi, Opsumit |
| Olympus America INC. | $20.63 | 2022 | |
| Csl Behring | $20.54 | 2025 | Hizentra |
| Axsome Therapeutics, INC. | $20.21 | 2025 | Sunosi |
| Hikma Pharmaceuticals USA | $18.25 | 2025 | Ryaltris |
| Viatris Specialty LLC | $15.35 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meera Ranganathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.